Elicio Therapeutics to host virtual KOL event on AMP-powered ELI-002

Elicio Therapeutics (ELTX) will host a virtual key opinion leader event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS driven pancreatic ductal adenocarcinoma, one of the most lethal and underserved solid tumors. The event will feature insights from leading experts: Darrell Irvine, Ph.D. – Department of Immunology & Microbiology, The Scripps Research Institute, Howard Hughes Medical Institute; Eileen O’Reilly, M.D. – FASCO Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center. The event will provide an overview of Elicio’s proprietary lymph node-targeting amphiphile platform, which underpins a pipeline of novel immunotherapies designed to generate potent and durable immune responses. The discussion will also focus on Elicio’s lead product candidate, ELI-002, an AMP-powered therapeutic vaccine designed to overcome immune evasion. ELI-002 is currently being evaluated in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC, and an event-driven disease-free survival interim analysis of the study is anticipated in Q3 2025.